צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Genetic Technologies (GENE)

The high authority of Genetic Technologies (GENE) in precision genomics is confirmed by the year-over-year (TTM) sales growth chart, where this metric equals 19.20. Revenues are based on tests for the detection of oncology and cardiological pathologies. The monetization of intellectual property through unique DNA analysis and partnerships with clinics ensures the expansion of the company's market presence.
Genetic Technologies (GENE) - פילוחי מדדים ודוחות פיננסיים

For a fundamental valuation of Genetic Technologies (GENE), it is critical to track trailing twelve-month (LTM) revenue dynamics, which measure the sales growth rate relative to the previous period. By analyzing the LTM annual sales growth rate on the GURU.Markets platform, an investor can discern the actual adoption speed of DNA tests in clinics, which, amid liquidity shortages and high personnel costs, directly determines the issuer's financial stability.